Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Cytokinetics Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.04 (market cap $534.51M), while Cytokinetics Inc trades at $62.02 (market cap $8.50B). The key difference: Cytokinetics Inc is far larger — about 15.9× GraniteShares 2x Long COIN Daily ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Cytokinetics Inc for 19 Days on average.
| CONL | CYTK | |
|---|---|---|
Market Cap | $534.51M | $8.50B |
Volume | 15,212,221 | 2,395,556 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $87.26 |
52-Week Low | $3.93 | $54.76 |
Typical Hold Time | 15 Days | 19 Days |
Enterprise Value | — | $8.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) is trading at $5.23, down 7.76% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, making it highly volatile. Recent news highlights significant price gaps and performance volatility, with one article noting an 85% decline when Coinbase fell 50%.
The outlook remains high-risk due to leveraged exposure to Coinbase volatility. Investment opportunity exists for speculative traders betting on Coinbase rebounds, but risks include amplified losses, tracking error, and crypto market sentiment swings. Caution is warranted given the bearish technical setup and leveraged structure.
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
